Summary
Andrew Huberman speaks with Dr. Matthew Hill, professor of cell biology and anatomy at the University of Calgary and an expert on cannabis biology, for a comprehensive discussion of how cannabis affects the brain and body. Dr. Hill explains the endocannabinoid system -- anandamide and 2-AG as the two primary endocannabinoids, CB1 receptors throughout the brain, and how THC mimics anandamide to produce its psychoactive effects including altered time perception, enhanced sensory pleasure, increased appetite ("the munchies"), and impaired short-term memory. He distinguishes between THC and CBD, noting that CBD has clear evidence only for pediatric epilepsy at high prescription doses.
The conversation addresses the most debated questions around cannabis: the relationship between cannabis use and psychosis/schizophrenia (genetic vulnerability appears to be the primary driver, not cannabis alone, though high-potency THC increases risk), whether cannabis is addictive (cannabis use disorder affects roughly 10% of regular users), the differences between smoking, vaping, and edibles in terms of pharmacokinetics and safety, effects on hormones (minimal at typical doses), and the complexity of strain differences (indica vs. sativa distinctions are largely marketing, not biology). Dr. Hill also discusses cannabis for pain, PTSD, anxiety, and nausea, emphasizing that the endocannabinoid system's primary role is stress buffering through anandamide signaling.
Key Points
- THC produces its effects by mimicking anandamide at CB1 receptors, altering time perception, enhancing appetite and taste, and impairing short-term memory formation
- CBD has clear clinical evidence only for pediatric epilepsy (Epidiolex) at high doses -- most consumer CBD products are too low-dose to produce pharmacological effects
- Cannabis use disorder affects roughly 10% of regular users, with tolerance, withdrawal, and compulsive use patterns similar to other substances
- The link between cannabis and psychosis is driven primarily by genetic vulnerability to schizophrenia, though high-potency THC concentrates increase risk
- Indica vs. sativa distinctions are largely marketing -- the subjective effects of cannabis are driven more by expectancy bias than by botanical classification
- The endocannabinoid system's primary function is stress buffering: anandamide in the amygdala constrains stress-induced cortisol release and fear responses
- Edibles produce different effects than inhaled cannabis because THC is converted to 11-hydroxy-THC in the liver, which is more potent and longer-lasting
Key Moments
THC carpet-bombs all brain CB1 receptors at once
Unlike natural endocannabinoids that act at specific synapses, THC activates every CB1 receptor simultaneously.
"THC, when it gets into your brain, is just blanket activation. You're carpet bombing the whole system indiscriminately."
Most CBD effects at typical doses are likely placebo
CBD gummies at 2-20mg are far below the 1500-2000mg used in epilepsy trials, making most reported effects likely placebo.
"In the pediatric epilepsy studies, the dose ranges are like 1,500 to 2,000 megs. And you're talking about a child who weighs 40 to 60 pounds."
